Shaking hands with the future through omics application in transfusion medicine and clinical biochemistry.

摘要: Two years have now passed since the first Blood Transfusion Special Issue initiative about “Proteomics Application in field of Medicine”. At end initiative, we could conclude that, despite elevated costs for adequate facilities and trained personnel, bet was open as to whether proteomics might utterly find a proper collocation transfusion medicine establishment. The success previous has been renewed 2012, with participation present special volume most leading researchers field. In thanking all contributors, care thank Dr. Vaglio Grazzini their interesting editorial current situation Italian service1. Two later, it emerged that other “Omics” disciplines and, particular, metabolomics, are indicated suitable candidates “new best act” award clinical biochemistry. With term disciplines, scientific community refers those which characterized by holistic rather than reductionistic approach, through investigation certain classes biomolecules whole complex system any give biological matrix. Biomolecule include example proteins (in proteomics), mRNAs transcriptomics), small molecule compound (metabolite) complement genome proteome, metabolome. The invaluable expertise accumulated upon decades laboratory science will soon result (and, emerge from papers included this issue, already has) implementation new powerful analytical technologies fields biochemistry. For example, Sparrow2 envisages role metabolomics analysis safety effectiveness currently licensed RBC additive solutions, well experimental designing testing storage systems. As Sparrow brilliantly summarizes, “it is time harness power “omics” answers remedies some specific issues concerns stored components”2. Omics application blood-derived labile products, such erythrocyte concentrates, also main topic around Cluitmans et al.3 Bosman’s group focused contribution. Analogously, Authors envisage changes membrane structure accompany red blood cells rapid removal bloodstream recipient significant percentage transfused cells. In our review collaboration Prof. Giardina4 highlighted upcoming need translating latest successes technological innovation chemistry setting. view, Omics seem perfectly serve purpose promise provide competitive edge challenge improve four areas, viz nanotechnology, predictive medicine, nutraceuticals regenerative promote dawn era chemistry. In article, Kriebardis colleagues5 Papassideri’s refer physiological responses conditions cellular aging per se, explain how they imprinted clear-cut modifications at molecular level. frame, focus on microparticles outline knowledge formation vitro, effect probable activities towards both “storage lesion” progression post-transfusion effects. Some ideas presented reviews further delved into original paper contributions. Canellini al.6 Tissot’s analyse cell antigens means flow cytometry localized erythrocytes-derived microparticles. These evidences support conclusion potential immunogenic cell-derived microparticles, owing capacity bind antibody. Red represented contribution Dumont Yoshida7, where proposed concentrates presence either SAGM or AS-3, based protein separation two-dimensional gel electrophoresis. study profile AS-3 appears be slightly different (better than) reports SAGM-stored counterparts. However, increase total spot number due fragments day 21 decrease 42 suggestive universal phenomenon not efficiently tackled none two solutions investigated study. Rinalducci al.8 oxidative stress caspase-mediated fragmentation cytoplasmic domain band 3 during storage. reported observation degradation products (CDB3), were detected membranes preservation medium. One these showed an apparent weight 34 kDa demonstrated product free-radical attack chain, whereas another fragment 24 caspase 3-mediated cleavage. mechanism appeared dependent state erythrocytes, phenomena significantly reduced under anaerobic conditions. Proteomics approaches successfully applied Thiele al.9 delve platelet lesions determine effects Amotosalen/UVA pathogen reduction treatment gamma irradiation LC-ESI-MS/MS. contribution, report 948 identified fluctuations over progress response each treatment. report, 1, amotosalen/UVA-treatment triggered alteration 23 proteins, 49 (overlap: 11 proteins). Five days revealed 58 (Amotosalen/UVA treated), 50 (gamma irradiated), 36 (controls) proteome compared one control platelets 1. while Amotosalen/UVA-treatment causes less pronounced results indicate 5 attributed treatment. Proteomics applications tied unexpected applications, doping autologous transfusion, emerges Marrocco colleagues10. Biomarkers vitro aged erythrocytes suggest winning strategies against transfusions purposes. Urbani al.11 provided proteomic materials adsorption haemodialysis, approach can critical assessment compare efficiencies dialyser plasma proteins. Selective categories indeed attracted great deal interest, Breen al.12 Josic’s group, propose high-throughput fractionation strategy human fast enrichment low- high-abundance proteins. comes solid (especially coagulation factors). scheme used screening order identify low high abundance prognostic diagnostic disease biomarkers. Applications omics related biochemistry, Sirolli al.13, who possible carnitine diabetic patients hemodialysis, only relation condition deficiency but lipid glucose homeostasis, typical patients. Finally, letters Editor Garcia’s14 Alves’15 discuss future perspectives efficiency service centers Brazil (Instituto Nacional de Câncer, Rio Janeiro), rapidly emerging tool routine practice. Two step undoubtedly taken. Proteomicists experts joined same table started shaking hands, shared goal worldwide always more basic science-aware fashion. While few ago there pillars, bridge finally there, ready crossed over.